Claims for Patent: 9,987,271
✉ Email this page to a colleague
Summary for Patent: 9,987,271
Title: | Method of treating nasopharyngeal carcinoma using perillyl alcohol derivative |
Abstract: | A method of treating nasopharyngeal carcinoma in a mammal includes delivering to the mammal a therapeutically effective amount of a perillyl alcohol (POH) carbamate which is a perillyl alcohol conjugated with temozolomide (TMZ). |
Inventor(s): | Chen; Thomas (La Canada, CA) |
Assignee: | NeOnc Technologies, Inc. (Los Angeles, CA) |
Application Number: | 15/429,556 |
Patent Claims: | 1. A method for treating oral cavity cancer in a mammal, the method comprising administering to the mammal a therapeutically effective amount of a perillyl alcohol
carbamate, wherein the perillyl alcohol carbamate comprises perillyl alcohol conjugated with temozolomide (TMZ).
2. The method of claim 1, wherein the oral cavity cancer is pharyngeal cancer. 3. The method of claim 2, wherein the pharyngeal cancer is nasopharyngeal carcinoma. 4. The method of claim 1, further comprising treating the mammal with radiation. 5. The method of claim 1, further comprising administering to the mammal one or more chemotherapeutic agents. 6. The method of claim 5, wherein the chemotherapeutic agent is selected from the group consisting of Rituximab, Beuacizumab, Trastuzumab, Imaninib, Lenalidomide, Pemetrexed, Bortezomib, Cetuximab, Leuprorelin, Abiraterone, 5-Fluorouracil, Doxorubicin, Epirubicin, Gemeitabine, Methotrexate, all trans Retinoic Acid, Azacitidine, Azathioprine, Bleomycin, Carboplatin, Capecitabine, Cisplatin, Chlorambucil, Cyclophosphoramide, Cytarabine, Daunorubicin, Docetaxel, Doxifluridine, Epothilone, Etoposide, Hydroxyurea, Idarubicin, Irinotecan, Mechlorethamine, Mercaptopurine, Mitoxantrone, Oxaliplatin, Paclitaxel, Teniposide, Tioguanine, Topotecan, Valrubicin, Vincristine, Vinblastine, Vindesine, Vinorelbine and combinations thereof. 7. The method of claim 1, wherein the perillyl alcohol carbamate is administered by inhalation, orally, intravenously, subcutaneously or intramuscularly. 8. The method of claim 7, wherein the perillyl alcohol carbamate is administered intranasally using an atomizer. 9. The method of claim 1, wherein the perillyl alcohol carbamate is 3-methyl 4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carbonyl)-ca- rbamic acid-4-isopropenyl cyclohex-1-enylmethyl ester. 10. The method of claim 1, wherein the perillyl alcohol carbamate is administered by a nasal delivery device. 11. The method of claim 10, wherein the nasal delivery device is selected from the group consisting of an intranasal inhaler, an intranasal spray device, an atomizer, a nebulizer, a metered dose inhaler (MDI), a pressurized dose inhaler, an insufflator, a unit dose container, a pump, a dropper, a nasal spray bottle, a squeeze bottle and a bi-directional device. |
Details for Patent 9,987,271
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genentech, Inc. | RITUXAN | rituximab | Injection | 103705 | 11/26/1997 | ⤷ Try a Trial | 2034-10-27 |
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 09/25/1998 | ⤷ Try a Trial | 2034-10-27 |
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 02/10/2017 | ⤷ Try a Trial | 2034-10-27 |
Eli Lilly And Company | ERBITUX | cetuximab | Injection | 125084 | 02/12/2004 | ⤷ Try a Trial | 2034-10-27 |
Eli Lilly And Company | ERBITUX | cetuximab | Injection | 125084 | 03/28/2007 | ⤷ Try a Trial | 2034-10-27 |
Genentech, Inc. | RITUXAN HYCELA | rituximab and hyaluronidase human | Injection | 761064 | 06/22/2017 | ⤷ Try a Trial | 2034-10-27 |
Genentech, Inc. | HERCEPTIN HYLECTA | trastuzumab and hyaluronidase-oysk | Injection | 761106 | 02/28/2019 | ⤷ Try a Trial | 2034-10-27 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.